These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22642177)

  • 1. [Oncolytic parvoviruses. A new approaches for cancer therapy].
    Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
    Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic parvoviruses as cancer therapeutics.
    Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
    Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
    Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
    Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-faceted mechanism of parvoviral oncosuppression.
    Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
    Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
    Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
    Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic parvoviruses: from basic virology to clinical applications.
    Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
    Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
    Akladios C; Aprahamian M
    Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
    Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
    Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
    Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
    Viruses; 2016 May; 8(5):. PubMed ID: 27213425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
    Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
    BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
    Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
    Viruses; 2022 May; 14(5):. PubMed ID: 35632759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
    Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
    Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells].
    Razumov IA; Sviatchenko VA; Protopopova EV; Kochneva GV; Kiselev NN; Gubanova NV; Shilov AG; Mordvinov VA; Netesov SV; Chumakov PM; Loktev VB
    Vestn Ross Akad Med Nauk; 2013; (12):4-8. PubMed ID: 24741936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
    Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.